A recently added report by Transparency Market Research (TMR) to its growing repository, titled, “Hospital Cancer Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024,” reports that the market is being propelled on account of the rising incidence of cancer and the growing awareness about its treatment worldwide..
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11501
The early diagnosis of cancer has become extremely critical for providing effective and accurate treatment. A patient may be subjected to variety of diagnostics tests both in hospitals as well as in the laboratories. Pap smear test was one of the earliest screening tests used for detecting cancer by the American Cancer Society. The significance of this test was that it aided in early diagnosis and treatment of cervical cancer, resulting in a declined death rate of cervical cancer patients by nearly 70.0%.
Innovation in healthcare, particularly in targeted disease screening tests, along with numerous initiatives undertaken by the regional governments and the WHO to reduce disease prevalence is expected to favorably impact the global hospital cancer diagnostics market growth. Rising adoption of western culture, unhealthy food habits and physical inactivity has upped the number of people suffering from various chronic diseases such as cancer. The global hospital cancer diagnostics market is segmented based on the type of cancer into lung cancer, breast cancer, bladder cancer, oral cancer, leukemia, lymphoma, uterine cancer, ovarian cancer, skin cancer, prostrate, colon and rectal cancers, stomach cancer, and others.
The most common methods utilized for cancer diagnosis in hospitals include laboratory tests (blood and urine tests), biopsy, endoscopy, diagnostic imaging, genetic tests, nuclear medicine scans (bone scans, etc.), and hematology tests. Diagnostic imaging for cancer diagnosis uses several techniques like x-rays, CT (computerized tomography) and CAT (computerized axial tomography) scans, magnetic resonance imaging (MRI), ultrasound, mammography and positron emission tomography (PET) scanning.
Some of the leading companies operating in the global hospital cancer diagnostics market are Applied Genetic Technologies Corporation, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd., Beckman Coulter/Danaher Corporation, GE Healthcare, and diaDexus, Inc.
The report utilizes various leading analytical tools to decipher the opportunities and restraints that players might come across while trying to progress in the market for hospital cancer diagnostics. It throws light on the key players’ product offerings, sales and revenues, market shares, and prospects in the coming future.